Molecular changes in fetal Down syndrome brain

Journal of Neurochemistry

Volumn 84, Issue 5, 2003, Pages 895-904

  Engidawork, Ephrem ^a   Lubec, Gert ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Brain; Cytoskeleton; Fetal Down syndrome; Mental retardation; Signalling

Indexed keywords

BIOCHEMISTRY; BRAIN; CHROMOSOME 21; CYTOSKELETON; DEVELOPMENTAL DISORDER; DOWN SYNDROME; FETUS; HUMAN; HUMAN TISSUE; MALE; MENTAL DEFICIENCY; MORPHOLOGY; NERVE DEGENERATION; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; TRISOMY;

APOPTOSIS; BRAIN; CYTOSKELETAL PROTEINS; DOWN SYNDROME; FETAL DISEASES; GENE DOSAGE; HUMANS; MENTAL RETARDATION; MORPHOGENESIS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 0037339732     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.01614.x     Document Type: Short Survey

References (73)

1. Arai Y., Mizuguchi M. and Takashima S. (1996) Excessive glutamate receptor 1 immuno-reactivity in adult Down syndrome brains. Pediatr. Neurol. 5, 203-206.
2. Arai Y., Suzuki A., Mizuguchi M. and Takashima S. (1997) Developmental changes in the expression of amyloid precursor protein in Down syndrome brain. Brain Dev. 19, 290-204.
3. Arai Y., Ijuin T., Takenawa T., Becker L. E. and Takashima S. (2002) Excessive expression of synaptojanin in brains with Down syndrome. Brain Dev. 24, 67-72.
4. Arenander A. T. and De Vellis J. (1994) Development of the nervous system, in Basic Neurochemistry (Siegel G. J., Agranoff B. W., Albers R. Y. and Molinoff P. B., eds), 5th edn, pp. 573-606. Raven Press, New York.
5. Azmitia E. C., Griffin W. S. T., Marshak D. R., Van Eldik L. J. and Whitaker-Azmitia P. M. (1992) S100β and serotonin: a possible astrocytic-neuronal link to neuropathology of Alzheimer's disease. Prog. Brain Res. 92, 459-473.
6. Baffico M., Perroni L., Rasore-quartino A. and Scartezzini P. (1989) Expression of the human ETS-2 oncogene in normal fetal tissues and in the brain of a fetus with trisomy 21. Hum. Genet. 83, 295-296.
7. Bahn S., Mimmack M., Ryan M., Caldwell M. A., Jauniaux E., Starkey M., Svendsen C. N. and Emson P. (2002) Neuronal target genes of the neuron-restrictive silencer factor in neurospheres derived from fetuses with Down's syndrome: a gene expression study. Lancet 359, 310-315.
8. Bajo M., Fruehauf J., Kim S. H., Fountoulakis M. and Lubec G. (2002) Proteomic evaluation of intermediary metabolism enzyme proteins in fetal Down syndrome cerebral cortex. Proteomics 2, 1539-1546.
9. Bar-Peled O., Gross-Isseroff R., Ben-Hur H., Hoskins I., Groner Y. and Biegon A. (1991) Fetal human brain exhibits a prenatal peak in the density of serotonin 5-HT1A receptors. Neurosci. Lett. 127, 173-176.
10. Becker L. E., Armstrong D. L. and Chan F. (1986) Dendritic atrophy in children with Down's syndrome. Ann. Neurol. 20, 520-532.
11. Behl C., Davis J., Lesley R. and Shubert D. (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77, 817-827.
12. Bhat N. K., Fisher R. J., Fujiwara S., Ascione R. and Rapas T. S. (1987) Temporal and tissue specific expression of mouse ETS genes. Proc. Natl Acad. Sci. USA 84, 3161-3165.
13. Brooksbank B. W. and Balazs R. (1984) Superoxide dismutase, glutathione peroxidase and lipoperoxidation in Down's syndrome brain. Brain Res. 318, 37-44.
14. Brooksbank B. W., Walker D., Balazs R. and Jorgensen O. S. (1989) Neuronal maturation in the foetal brain in Down's syndrome. Early Hum. Dev. 18, 237 246.
15. Buday L. (1999) Membrane-targeting of signaling molecules by SH2/SH3 domain-containing adaptor proteins. Biochim. Biophys. Acta 1422, 187-204.
16. Busciglio J. and Yankner B. A. (1995) Apoptosis and increased generation of active oxygen species in Down syndrome neurons in viro. Nature 378, 776-779.
17. Cheon M. S., Fountoulakis M., Dierssen M., Ferreres J. C. and Lubec G. (2001) Expression profiles of proteins in fetal brain with Down syndrome. J. Neural Transm. Suppl. 61, 311-319.
18. D'Adamo P., Menegon A., Lo Nigro C., Grasso M., Tamanini F., Bienvenu T., Gedeon A., Oostra B., Wu S. K., Tandon A., Valtorta F., Balch W., Chelly J. and Toniolo D. (1998) Mutation in the GDII are responsible for X-linked non-specific mental retardation. Nat. Genet. 19, 134-139.
19. Eaton B. A., Fetter R. D. and Davis G. W. (2002) The dynactin protein complex is an essential determinant of synapse stability. Neuron 34, 729-741.
20. Engidawork E., Balic N., Fountoulakis M., Dierssen M., Graber-Platzer S. and Lubec G. (2001a) β-Amyloid precursor protein, ETS-2 and collagen alpha 1 (VI) chain precursor, encoded on chromosome 21, are not overexpressed in fetal Down syndrome: further evidence against gene dosage effect. J. Neural Transm. Suppl. 61, 335-346.
21. Engidawork E., Balic N., Juranville J.-F., Fountoulakis M. and Lubec G. (2001b) Unaltered expression of Fas, caspase 3, Bcl-2, and annexins in brain of fetal down syndrome: evidence against increased apoptosis. J. Neural Transm. Suppl. 61, 149-162.
22. Epstein J. (2001) Down syndrome, in The Metabolic and Molecular Bases of Inherited Disease (Scriver C. R., Beaudet A. L., Sly W. S. and Valle D., eds), 7th edn, Vol. 1, pp. 1223-1256. McGraw-Hill, Inc., New York.
23. Freidl M., Gulesserian T., Lubec G., Fountoulakis M. and Lubec B. (2001) Deterioration of the transcriptional, splicing and elongation machinery in brain of fetal Down syndrome. J. Neural Transm. Suppl. 61, 47-57.
24. Fuentes J. J., Genesca L., Kingsbury T. J., Cunningham K. W., Perez-Riba M., Estivill X. and de la Luna S. (2000) DSCR1, over-expressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Hum. Mol. Genet. 9, 1681-1690.
25. Galdzicki Z., Siarey R., Pearce R., Stoll J. and Rapoport S. I. (2001) On the cause of mental retardation in Down syndrome: extrapolation from full and segmental trisomy 16 mouse models. Brain Res. Rev. 35, 115-145.
26. Golden J. A. and Hyman B. T. (1994) Development of the superior temporal neocortex is anomalous in trisomy 21. J. Neuropathol. Exp. Neurol. 53, 513-520.
27. Griffin W. S. T., Sheng J. G., McKenzie L. E., Royston M. C., Gentleman S. M., Brumback R. A., Cork L. C., Del Bigio M. R., Roberts G. W. and Mrak R. E. (1998) Life-long over-expression of S100β in Down's syndrome: implications for Alzheimer's pathogenesis. Neurobiol. Aging 19, 401-405.
28. Gulesserian T., Engidawork E., Fountoulakis M. and Lubec G. (2001) Antioxidant proteins in fetal brain: superoxide dismutase-1 is not over-expressed in fetal Down syndrome. J. Neural Transm. Suppl. 61, 71-84.
29. Gulesserian T., Kim S. H., Fountoulakis M. and Lubec G. (2002) Aberrant expression of centractin and capping proteins, integral constituents of the dynactin complex, in fetal Down syndrome brain. Biochem. Biophys. Res. Commun. 291, 62-67.
30. de Haan J. B., Wolvetang E. J., Cristiano F., Iannello R., Bladier C., Kelner M. J. and Kola I. (1997) Reactive oxygen species and their contribution to pathology in Down syndrome. Adv. Pharmacol. 38, 379-402.
31. Hattori M., Fujiyama, A., Taylor T. D., Watanabe H., Yada T., Park H.-S. et al. (2000) The DNA sequence of human chromosome 21. Nature 405, 311-319.
32. Huang X., Cuajungco M. P., Atwood C. S., Hartshorn M. A., Tyndall J. D., Hanson G. R., Stokes K. C., Leopold M., Multhaup G., Goldstein L. E., Scarpa R. C., Saunders A. J., Lim J., Moir R. D., Glabe C., Bowden E. F., Masters C. L., Fairlie D. P., Tanzi R. E. and Bush A. I. (1999). Cu (II) potentiation of Alzheimer amyloid beta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 274, 37111-37116.
33. Ishikawa R., Hayashi K., Shirao T., Xue Y., Takagi T., Sasaki Y. and Kazuhiro K. (1994) Drebrin, a development-associated brain protein from rat embryo causes the dissociation of tropomyosin from actin filaments. J. Biol. Chem. 269, 29928-29933.
34. Keene J. D. (2001) Ribonucleoprotein infrastructure regulating the flow of genetic information between the genome and the proteome. Proc. Natl Acad. Sci. USA 98, 7018-7024.
35. King S. J. and Schroer T. A. (2000) Dynactin increases the processivity of the cytoplasmic dynein motor. Nat. Cell Biol. 2, 20-24.
36. Klein W., Kraft G. A. and Finch C. E. (2001) Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum. Trends Neurosci. 24, 219-224.
37. Kuan C.-Y., Roth K. A., Flavell R. A. and Rakic P. (2000) Mechanisms of programmed cell death in the developing brain. Trends Neurosci. 23, 291-297.
38. Labudova O., Kitzmueller E., Rink H., Cairns N. and Lubec G. (1999) Gene expression in fetal Down syndrome brain as revealed by subtractive hybridization. J. Neural Transm. Suppl. 59, 125-136.
39. LaMonte B., Wallace K. E., Holloway B. A., Shelly S. S., Ascano J., Tokito M., Van Winkle T., Howland D. S. and Holzbaur E. L. F. (2002) Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 34, 715-727.
40. Liliental J. and Chang D. D. (1998) RACK1, a receptor for activated protein kinase C, interacts with integrin β subunit. J. Biol. Chem. 273, 2379-2383.
41. Longo V. D., Viola K. L., Klein W. L. and Finch C. E. (2000) Reversible inactivation of superoxide sensitive aconitase in Aβ42 treated neuronal cell lines. J. Neurochem. 75, 1977-1985.
42. Lubec B., Weitzdoerfer R. and Fountoulakis M. (2001a) Manifold reduction of moesin in fetal Down syndrome brain. Biochem. Biophys. Res. Commun. 286, 1191-1194.
43. Lubec B., Yoo B. C., Dierssen M., Balic N. and Lubec G. (2001b) Down syndrome patients start early prenatal life with normal cholinergic; monoaminergic, and serotonergic innervation. J. Neural Transm. Suppl. 61, 303-310.
44. Marin-Padilla M. (1976) Pyramidal cell abnormalities in the motor cortex of a child with Down's syndrome. J. Comp. Neurol. 167, 63-75.
45. Mochly-Rosen D., Khaner, H. and Lopez J. (1991) Identification of intracellular receptor proteins for activated protein kinase C. Proc. Natl Acad. Sci. USA 88, 3997-4000.
46. Nicolaidis P. and Petersen M. B. (1998) Origin and mechanisms of nondisjunction in human autosomal trisomies. Hum. Reprod. 13, 313-319.
47. Odetti P., Angelini G., Dapino D., Zaccheo D., Garibaldi S., Dagna-Bricarelli F., Piombo G., Perry G., Smith M., Traverso N. and Tabalon M. (1998) Early glycooxidation damage in brains from Down syndrome. Biochem. Biophys. Res. Commun. 243, 849-851.
48. Oka A. and Takashima S. (1999) The up-regulation of metabotropic receptor 5 (mGluR5) in Down syndrome brain. Acta Neuropathol. 97, 275-278.
49. Ostrerova N., Petrucelli L., Farrer M., Mehta N., Choi P., Hardy J. and Wolozin B. (1999) Alpha synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 19, 5782-5791.
50. Peyril A., Weitzdoerfer R., Gulesserian T., Fountoulakis M. and Lubec G. (2002) Aberrant expression of signaling-related proteins 14-3-3 gama and RACK1 in fetal Down syndrome brain (trisomy 21). Electrophoresis 23, 152-157.
51. Postel E. H. and Ferrone C. A. (1994) Nucleoside diphosphate kinase enzyme activity of NM23-H2/PVF is not required for its DNA binding and in vitro transcriptional functions. J. Biol. Chem. 269, 8627-8630.
52. Postel E. H., Berberich S. J., Flint S. J. and Ferrone C. A. (1993) Human c-myc transcription factor PuF identified as nm23-H2 nucleoside diphosphate kinase, a candidate suppressor tumor metastasis. Science 291, 478-480.
53. Pritchard M. A. and Kola I. (1999) The 'gene dosage effect' hypothesis versus the 'amplified developmental instability' hypothesis in Down syndrome. J. Neural Transm. Suppl. 57, 293-304.
54. Pucharcós C., Fuentes J.-J., Casas C., de la Luna S. Alcántara S., Arbonés M. L., Soriano E., Estivill X. and Pritchard M. (1999) Alu-splice cloning of the human intersectin (ITSN), a putative multivalent binding protein expressed in proliferating and differentiating neurons and over-expressed in Down syndrome. Eur. J. Hum. Genet. 7, 704-712.
55. Raouf A. and Seth A. (2000) Ets transcription factors and targets in osteogenesis, Oncogene 19, 6455-6463.
56. Schmidt-Sidor B., Wisniewski K. E., Shepard T. H. and Sersen E. A. (1990) Brain growth in Down syndrome subjects 15-22 weeks of gestation age and birth to 60 months. Clin. Neuropathol. 4, 181-190.
57. Shapiro B. L. (1999) The Down Syndrome critical region. J. Neural Transm. Suppl. 57, 41-60.
58. Skoulakis E. M. S. and Davis R. L. (1998) 14-3-3 proteins in neuronal development and function. Mol. Neurobiol. 16, 269-284.
59. Sumarsono S. H., Wilson T. J., Tymms M. J., Venter D., Corrick C. M., Kola R., Lahoud M., Papas T. S., Seth A. and Kola I. (1996) Ets transgenic mice develop skeletal abnormalities analogous to those found in Down syndrome. Nature 379, 534-537.
60. Takashima S., Becker L. E., Armstrong D. L. and Chan F. (1981) Abnormal neuronal development in the visual cortex of the human fetus and infant with Down's syndrome. A quantitative and qualitative Golgi studies. Brain Res. 225, 1-21.
61. Teller J. K., Russo C., DeBusk L. M., Angelini G., Zaccheo D., Dagna-Bricarelli F., Scartezzini P., Bertolini S., Mann D. M. A., Tabaton M. and Gambetti P. (1996) Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nat. Med. 2, 93-95.
62. Vialard F., Toyama K., Vemoux S., Carlson E. J., Epstein C. J., Sinet P. M. and Rahmani Z. (2000) Over-expression of mSim2 gene in the zona limitans of the diencephalon of segmental trisomy 16 Ts1Cje fetuses, a mouse model for trisomy 21: a novel whole-mount RNA hybridization assay. Dev. Brain Res. 121, 73-78.
63. Watanabe M., Isobe T., Ichimura T., Kuwano R., Takahashi Y. and Kondo H. (1993) Molecular cloning of rat cDNAs for beta and gama subtypes of 14-3-3 protein and developmental changes in expression of their mRNAs in the nervous system. Mol. Brain Res. 17, 135-146.
64. Weitzdoerfer R., Dierssen M., Fountoulakis M. and Lubec G. (2001a) Fetal life in Down syndrome starts with normal neuronal density but impaired dendritic spines and synaptosomal structure. J. Neural Transm. Suppl. 61, 59-70.
65. Weitzdoerfer R., Fountoulakis M., Dierssen M. and Lubec G. (2001b) Aberrant expression of dihydropyrimidinase-related proteins-2-3, and -4 in fetal Down syndrome brain. J. Neural Transm. Suppl. 61, 95-107.
66. Weitzdoerfer R., Stolzlechner D., Dierssen M., Ferreres J., Fountoulakis M. and Lubec G. (2001c) Reduction of nucleoside diphosphate kinase B, Rab GDP-dissociation inhibitor beta, and histidine triad nucleotide binding protein in fetal Down syndrome brain. J. Neural Transm. Suppl. 61, 347-359.
67. Weitzdoerfer R., Fountoulakis M. and Lubec G. (2002) Reduction of actin-related protein complex 2/3 in fetal Down syndrome. Biochem. Biophys. Res. Commun. 293, 836-841.
68. Whitaker-Azmitia P. M. (2001) Serotonin and brain development: role in human developmental diseases. Brain Res. Bull. 56, 479-485.
69. Wierzba-Bobrowicz T., Lewandowska E., Schmidt-Sidor B. and Gwiazda E. (1999) The comparison of microglia maturation in CNS of normal human fetuses and fetuses with Down's syndrome. Folia Neuropathol. 37, 227-234.
70. Wisniewski K. E. (1990) Down syndrome children often have brain with maturation delay, retardation of growth, and cortical dysgenesis. Am. J. Med. Genet. 7 (Suppl.), 274-281.
71. Wisniewski K. E. and Schmidt-Sidor B. (1989) Posmatal delay of myelin formation in brains from Down syndrome infants and children. Clin. Neuropathol. 8, 55-62.
72. Yan S. D., Fu J., Soto C., Chen X., Zhu H., Al-Mohanna F., Collison K., Zhu A., Stern E., Saido T., Tohyama M., Ogawa S., Roher A. and Stern D. (1997) An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature 389, 689-695.
73. Yarwood S., Steele M. R., Scotland G., Houslay M. D. and Bolger G. B. (1999) The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform. J. Biol. Chem. 274, 14909-14917.